For research use only. Not for use in humans.

Sotigalimab (Anti-TNFRSF5 / CD40)

Synonyms: APX005M Cat.No.A2635 Purity:99%

Sotigalimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody targeting CD40. It can be used for the research of metastatic pancreatic adenocarcinoma.MW :144.54 KD.

Quality Control

Batch: Purity: 99% Protein concentration: 6.095mg/ml Endotoxin Level: ＜1EU/mg

Specificity

Name	Citation	CD38	CD45	CD39	CD88	CD73	Others
RBN013209	0	++
MK-0159	0	+++
CD38 inhibitor 1 (compound 78c)	7	+++
AB680	0					++++
NQ301	1		+				TXA2 receptor
SodiuM Metatungstate	3			++
PMX-53	3				✔
LY-3475070	2					✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Sotigalimab (Anti-TNFRSF5 / CD40) is an agonistic monoclonal antibody targeting CD40. It can be used for the research of metastatic pancreatic adenocarcinoma.MW :144.54 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/33387490/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	2305607-45-6
Molecular Weight	144.54
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.